Results 231 to 240 of about 5,889,184 (390)

The Clinical Relevance of Tumor Biomarkers in Prostate Cancer-A Review. [PDF]

Cancers (Basel)
Majewska Z, Zajkowska M, Pączek S, Nowiński AR, Sokólska W, Gryko M, Orywal K.   +6 more
europepmc   +1 more source

Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials [PDF]

, 2016
S. Chowdhury, Neal D. Shore, Fred Saad, Celestia S. Higano, Karim Fizazi, Peter Iversen, K. Miller, Axel Heidenreich, Takeshi Ueda, C.S. Kim, D. Phung, Andrew Krivoshik, Feng-jing Wang, Kaijie Wu, Bertrand Tombal   +14 more
openalex   +1 more source

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

New England Journal of Medicine, 2004
D. Petrylak, C. Tangen, M. Hussain, P. Lara, Jeffrey A. Jones, M. Taplin, P. Burch, D. Berry, C. Moinpour, M. Kohli, M. Benson, E. Small, D. Raghavan, E. Crawford   +13 more
semanticscholar   +1 more source

CRISPRa Lipid Nanocomplex‐Mediated Mt3 Targeting Enhances Astrocytic Endocytosis of Amyloid‐β in an Alzheimer's Disease Mouse Model

Advanced Science, EarlyView.
GeTe exhibits intrinsically high carrier concentrations that limit its thermoelectric performance. Herein, CuAgSe alloying synergistically tunes the band structure, induces band flattening and valence‐band convergence, promotes Cu‐ion delocalization, and generates multiscale hierarchical structures to suppress phonon transport.
Junhang Park, Boyoung Kim, Minki Ha, Moonsu Park, Hongji Ryu, Hyerin Yu, Sungsoo Park, Yoon‐Seok Roh, Key‐Hwan Lim, Jin Tae Hong, Sang‐Bae Han, Chun‐Woong Park, Seok‐Beom Yong, Hanseul Park   +13 more
wiley   +1 more source

Reprogramming prostate cancer through the microbiome. [PDF]

Front Med (Lausanne)
Bautista J, Cardona-Maya WD, Gancino-Guevara K, López-Cortés A.   +3 more
europepmc   +1 more source

Diagnostic Accuracy of Urinary PCA3 for Prostate Cancer in Thai Patients With PSA Levels of 3 to 10 ng/ml Undergoing an Initial Prostate Biopsy

, 2023
Pasin Limudomporn, Nuankanya Sathirapongsasuti, Suchin Worawichawong, Pokket Sirisreetreeru, Wisoot Kongcharoensombat, Kittinut Kijvikai, Samapat Jittawera, Jitpanu Kocharoenwat, Pocharapong Jenjitranant   +8 more
openalex   +1 more source

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

New England Journal of Medicine, 2015
C. Sweeney, Yu‐Hui Chen, M. Carducci, Glenn Liu, D. Jarrard, M. Eisenberger, Y. Wong, N. Hahn, M. Kohli, M. Cooney, R. Dreicer, N. Vogelzang, J. Picus, D. Shevrin, M. Hussain, Jorge A. Garcia, R. DiPaola   +16 more
semanticscholar   +1 more source

Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma

Advanced Science, EarlyView.
IDH‐mutant gliomas exhibit sensitivity to PARP inhibitors (PARPi) owing to oncometabolite 2‐HG‐induced DNA repair defects. PARPi treatment induces resistance by upregulating Prickle4, which promotes VEGF‐driven angiogenesis. Combining PARPi veliparib with anti‐angiogenic lenvatinib blocks this pathway, causing tumor regression and prolonged survival in
Ju Yang, Hua Yang, Yifan Yuan, Chenyang Zhang, Ziwei Fu, Yanyan Chen, Yinghong Xiong, Shuyu Chen, Kexin Ling, Ying Liu, Jason T. Huse, Bo Chen, Timothy A. Chan, Zengxin Qi, Zhao Zhang, Xiuping Liu, Yuxiang Wang   +16 more
wiley   +1 more source

CDC7 is a targetable regulator of advanced prostate cancer. [PDF]

Sci Rep
Hartono AB, Hwang H, Paparaju S, Liu S, Brooks JD, Corey E, Stoyanova T.   +6 more
europepmc   +1 more source

Prostate Cancer

Oncology Times, 2004
openaire   +2 more sources